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Objectives. A multicenter pilot study was instituted to assess 
the role of intracoronary thrombolytic therapy during angioplasty 
for ischemic rest angina. 
Background. Acute thrombotic coronary occlusion is in-
creased during angioplasty for unstable angina, and intracoro-
nary thrombolytic agents have been used to maintain patency. 
Prophylactic use of intracoronary thrombolytic agents has been 
advocated in certain high risk subgroups, although no studies 
have randomized therapy. 
Methods. Ninety-three patients with either unstable angina 
and pain at rest (trial A, 66 patients) or postinfarction pain at rest 
(trial B, 27 patients) were randomized in double-blind fashion to 
administration of either intracoronary urokinase, 150,000 U, or 
saline solution placebo given immediately before angioplasty. 
Cineangiograms of the culprit lesion were recorded and analyzed 
In blinded fashion by a core laboratory for definite or possible 
(haziness) filling defects 15 min after angioplasty or after acute 
closure_ 
Results. Urokinase decreased filling defects at 15 min after 
Thrombus formation is important both in the pathogenesis of 
the acute coronary syndromes of unstable angina and acute 
myocardial infarction and as a mechanism of acute vessel 
closure after angioplasty (1-4). Although thrombolytic ther-
apy has been effective in treating acute myocardial infarc-
tion, its role in the acute management of unstable angina has 
been disappointing (5). However, recent reports indicate a 
potential role for thrombolytic therapy in treating acute 
closure after angioplasty in both syndromes (4,6-8). It' has 
also been suggested that prophylactic thrombolytic therapy 
may be of some benefit in high risk patients before angio-
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angioplasty in comparison with placebo (14% vs. 29%, respec-
tively, p = 0.08). Four patients in each treatment group developed 
acute vessel closure. However, although urokinase significantly 
reduced the incidence of filling defects in trial A (3% vs. 23%, 
p = 0.03), the drug had no effect at the selected dose in trial B 
(42% vs. 43%, respectively). Acute vessel closure occurred signif-
icantly more frequently in trial B than in trial A, and urokinase at 
the selected dose also had no effect. Ischemic events after angio-
plasty appeared to be related more to dissection than to throm-
bosis, although redilation, which was more frequent after placebo 
administration, may have reduced their incidence as well as that 
of acute closure. 
Conclusions. These data suggest a possible role for intracoro-
nary urokinase during angioplasty for unstable angina. The lack 
of effect after infarction may represent a greater thrombus burden 
or degree of plaque disruption. A trial utilizing higher doses of 
urokinase in a larger patient group is in progress. 
(J Am CoU CardioI1992;20:1197-204) 
plasty (9). Because no study has prospectively evaluated the 
efficacy of thrombolytic agents during angioplasty, the aim 
of the present pilot study was to assess in a double-blind 
randomized fashion the potential role of thrombolytic ther-
apy as an adjunct to angioplasty for ischemic rest angina in 
decreasing thrombus formation, acute vessel closure and 
ischemic events. 
Methods 
The Thrombolysis and Angioplasty in Unstable Angina 
(TAUSA) trial is a multicenter double-blind randomized 
study to assess the utility of urokinase versus placebo in 
preventing acute thrombotic closure during angioplasty for 
unstable angina. The primary end points are the angio-
graphic incidence of acute closure and thrombus formation 
after angioplasty and the postprocedure incidence of clinical 
in-hospital ischemia or infarction and coronary bypass sur-
gery. 
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Inclusion criteria. The following patients were eligible for 
enrollment in this pilot study: 
1. All patients undergoing angioplasty for unstable an-
gina who had one or more episodes of ischemic chest pain at 
rest of ~5 min duration and occurring <7 days before angio-
plasty. This group was designated the trial A study group. 
2. Trial B included patients with a non-Q wave myocar-
dial infarction that occurred within 7 days of angioplasty or 
a Q wave infarction that occurred within 30 days of angio-
plasty if it was associated with recurrent pain at rest that had 
begun within 7 days of angioplasty. Angina at rest after 
infarction was included in this study of unstable angina on 
the basis of the Braunwald classification of unstable angina 
(10) and because it is a common indication for angioplasty. 
Recurrent rest pain was not necessarily required after non·Q 
wave myocardial infarction because of the often subtle 
clinical distinction between ischemic pain at rest defined as 
unstable angina and that associated with elevation of cre-
atine kinase (CK) levels or persistent ST-T changes. 
3. All patients had to have an identifiable "culprit" lesion 
of ~70% diameter stenosis by visual inspection that was 
amenable to coronary angioplasty. 
Non-Q wave infarction was defined as ischemic chest 
pain associated with persistent ST or T wave changes 
(lasting at least 48 h) or an increase in CK greater than twice 
the upper limits of normal, or both. Q wave myocardial 
infarction was defined as ischemic chest pain at rest associ-
ated with the formation of new diagnostic Q waves in at least 
two contiguous frontal or precordial leads. This separation 
of trial A from trial B was prospectively defined before the 
start of the study because it was assumed that thrombus 
formation in the coronary arteries might be greater for 
patients with myocardial infarction than for those with 
unstable angina and perhaps the former patients would 
require a higher dose of thrombolytic therapy. Although it 
was finally decided for logistic reasons to use the same dose 
of urokinase in trials A and B, this distinction was main-
tained for the duration of the pilot study. 
Exclusion criteria. Patients undergoing angioplasty who 
otherwise would have met the criteria for trial A or B were 
excluded from randomization if any of the following was 
present: 1) age >75 years, 2) hematocrit <30%, 3) history of 
prior intracerebral bleeding or bleeding diathesis or recent 
«6 months) significant gastrointestinal bleeding, 4) signifi-
cant hypertension with blood pressures consistently 
>190/110 mm Hg, 5) membership in the Jehovah's Witness 
religious sect. 
Study protocol. Before angioplasty. Before the study all 
patients signed informed consent forms for angioplasty and 
for participation iri the study protocol. This protocol was 
approved by the Institutional Review Board of each institu-
tion. Patients already receiving aspirin were pretreated with 
80 mg of oral aspirin on the day of the procedure or 325 mg 
if they were not already receiving aspirin therapy. After 
vascular access was gained, 10,000 U of heparin was admin-
istered intravenously. Additional heparin during the proce-
dure was strongly advised and was given according to the 
usual policy of each participating laboratory. After 75 p.g of 
intracoronary nitroglycerin was given, the culprit lesion was 
visualized in orthogonal views. The views were selected that 
best visualized the lesion without vessel overlap or fore-
shortening. Ionic dyes were used to avoid the potential 
problems of increased thrombus formation found with 
nonionic dyes (11). Patients were then randomized in dou-
ble-blind fashion to receive either urokinase or saline solu-
tion placebo. Randomization was performed by the hospital 
pharmacy at each participating institution. Study drug was 
delivered to the catheterization laboratory in a 50-ml sy-
ringe. Either 150,000 U of urokinase or saline placebo 
(volume 30 ml) was infused for 5 min into the ostium (right or 
left main) of the CUlprit vessel. Urokinase was chosen rather 
than streptokinase because of the potential for allergic 
reactions with the latter. Because tissue-type plasminogen 
activator was not approved for intracoronary use, it was not 
considered a possible thrombolytic agent for this trial. The 
culprit lesion was then visualized again in the same orthog-
onal views after administration of 75 p.g of intracoronary 
nitroglycerin. 
During and after angioplasty. Angioplasty was per-
formed in routine fashion. Each angiographer was asked to 
assess whether additional balloon inflations were required 
during the procedure to treat acute vessel closure, ischemic 
chest pain or other conditions before completion of the 
study. When the angiographer was satisfied with the final 
results, a final (I-min) angiogram was taken. The wire was 
then removed and no further injections were made until 
15 min after the procedure. At that time a cine film of the 
angioplasty site was again obtained in the same orthogonal 
views after intracoronary administration of nitroglycerin. If 
necessary, each angiographer could redilate after the I5-min 
cine film because of acute closure, the presence of an 
intracoronary thrombus, significant dissection or for other 
causes of an inadequate angioplasty result. Additional injec-
tions were not allowed between 1 and 15 min after angio-
plasty unless the patient experienced chest pain or hemody-
namic compromise, or both. Patients were treated overnight 
with intravenous heparin, and the sheath was removed on 
the following day. The heparin was infused to maintain the 
partial thromboplastin time at a level of approximately twice 
the normal level. 
Core Laboratory Analysis 
Definitions of successful angioplasty, lesion morphology 
and flow. Each film was analyzed in blinded manner by the 
same two investigators at the core laboratory. Quantitative 
analysis was not performed for the pilot study. Successful 
angioplasty was defined as a lesion that appeared to have a 
<50% diameter stenosis after angioplasty. Each film was 
qualitatively analyzed for coronary morphology and Throm-
bolysis in Myocardial Infarction (TIMI) flow, as well as any 
qualitative change after urokinase or placebo therapy. Cul-
AMBROSE ET AL. 1199 JACC Vol. 20, No.5 
November I, 1992:1197-204 ADJUNCTIVE THROMBOLYTIC THERAPY FOR ANGIOPLASTY 
prit lesions that were <100% occluded before angioplasty 
were categorized as either concentric smooth or irregular, 
eccentric smooth or irregular (type II eccentric) or having 
multiple irregularities according to a modification of the 
classification of Ambrose and Israel (12). Complex lesions 
were defined as either eccentric or concentric irregular 
lesions or any lesion with a filling defect proximal or distal to 
the culprit lesion. Flow was categorized as TIMI flow grade 
o to III (13). Lesions were classified as totally occluded if 
TIMI flow grade 0 or I was present before angioplasty. 
Definition of thrombus, acute vessel closure and dissection. 
At 15 min after angioplasty, lesions were classified as with or 
without thrombus formation. Definite thrombus after angio-
plasty was defined as one or more filling defects at the site of 
dilation, and possible thrombus was defined as haziness or 
lucency at the site of dilation. Acute vessel closure was 
defined as a decrease in TIMI flow grade to flow grade 0 or 
1 with recurrent stenosis similar to or worse than that 
present before angioplasty. When possible, the mechanism 
of acute closure was categorized as either thrombotic or 
secondary to dissection. If a spiral dissection was present, it 
was assumed that dissection was the mechanism for acute 
closure. Acute closure associated with filling defects without 
dissection or with a dissection that was only a linear extralu-
minal cap in orthogonal views without lumen compromise 
was presumed to be thrombotic. If spiral dissection was 
present or any dissection with lumen compromise, lumen 
haziness (possible thrombus) was assumed to be part of the 
dissection and not considered as thrombus. Cine films were 
viewed on a Vanguard XR-35 and magnified fourfold for the 
detection of thrombus. 
Definitions of angiographic, procedural and clinical suc-
cess. For analysis between groups, indexes were defined to 
assess the relative success of a procedure. Angiographic 
success was defined as a <50% residual stenosis and the 
absence of acute vessel closure and definite or possible filling 
defects at 15 min after angioplasty. Procedural success was 
defined as all of these in addition to the absence of the need 
for redilation during the procedure or at or after 15 min after 
angioplasty. Clinical success was defined as a successful 
angioplasty without in-hospital recurrent ischemia, myocar-
dial infarction, bypass surgery or death. 
In-hospital follow-up studies. In-hospital follow-up was 
performed for evidence of recurrent ischemia, myocardial 
infarction, the need for urgent coronary bypass surgery or 
death. Recurrent ischemic pain was defined as chest pain 
similar to that occurring with balloon inflation and associated 
with ischemic ST-Twave changes. Serial samples of creatine 
kinase (CK) were drawn in patients who experienced isch-
emic pain with ST-T changes after angioplasty. Myocardial 
infarction was defined as recurrent pain associated with CK 
elevations or with diagnostic ECG changes. 
Fibrinogen levels were drawn before urokinase or pla-
cebo infusion at the end of the procedure and when possible 
12 to 24 h after angioplasty. Fibrinogen levels were mea-
sured in each participating hospital by heat precipitation. 
Enrollment 
Randomization Placebo Urokinase 
Exclusions 
Analysis 
Figure 1. Diagram of Thrombolysis and Angioplasty in Unstable 
Angina (TAUSA) pilot study patients enrolled, randomized, ex-
cluded and analyzed. A = trial A; B = trial B. 
Bleeding complications were defined as a decrease in hem-
atocrit of >5% points, the presence of a large hematoma or 
the need for transfusion during or after the procedure. 
Statistical analysis. Quantitative variables were analyzed 
with analysis of variance techniques to test for differences 
between treatment groups. Categoric variables were tested 
with Pearson's uncorrected chi-square test for overall differ-
ence between treatment groups. Treatment differences 
within each subset of patients were analyzed with the Fisher 
exact test. The same test procedure was used to analyze for 
differences between trial A and trial B. 
Because this investigation was only a pilot study, a 
sample size of 100 patients was planned. The final overall 
sample size was 93 patients: 50 in the placebo group and 43 
in the urokinase group. The actual sample sizes used in the 
analysis of each individual variable varied according to the 
availability of information for that particular variable. 
Results 
Patient study group (Fig. 1). Ninety-nine patients were 
enrolled in the pilot study. Ninety-three patients underwent 
angioplasty and 92 had films available for review. Of the six 
patients enrolled but not included in the final analysis, three 
had lesions that could not be crossed with the wire or by the 
balloon catheter, two had a CUlprit lesion that was improp-
erly identified according to the core laboratory, and one 
patient had an aborted angioplasty procedure because the 
guide wire caused dissection. Of the 93 remaining patients, 
50 were assigned to the placebo and 43 to the urokinase 
group; 66 were in trial A and 27 in trial B (Fig. I). 
Baseline clinical characteristics (Table 1). Pertinent angio-
plasty clinical data for the entire group of 99 patients are 
shown in Table 1. Although ages were similar in placebo and 
urokinase groups, there was a higher proportion of men in 
the placebo group (74% vs. 60%), but this difference was not 
significant. Risk factors for coronary disease showed no 
difference except for hypercholesterolemia (cholesterol 
>240 mg/dl) , which was present in a significantly higher 
proportion of patients assigned to urokinase than to placebo 
(69% vs. 44%, p < 0.01). Drug therapy was also similar 
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Table 1. Baseline Clinical Characteristics and Drug Therapy of 
the Patients in the Two Study Groups 
Placebo Urokinase 
(n = 54) (n = 45) 
Age (yr, mean) 60 59 
Male (%) 40 (74) 27 (60) 
Risk factors 
Hypertension 32 (59) 29 (64) 
Diabetes 14 (26) 11 (24) 
Hypercholesterolemia* 24 (44) 31 (69) 
Smoking 19 (35) 15 (33) 
Chronic angina 25 (46) 23 (51) 
Previous MI 19 (35) 18 (33) 
Drug therapy 
Beta-blockers (before admission) 25 (46) 21 (47) 
Aspirin (before admission) 30 (56) 22 (49) 
Aspirin (after admission) 41 (76) 32 (71) 
IV nitroglycerin 16 (30) 19 (42) 
IV heparin 38 (70) 26 (58) 
Fibrinogen (mg/dl) 356 ± 110 344 ± 83 
*p = 0.01, comparing the urokinase and placebo groups. Unless otherwise 
indicated, data are presented as mean value ± SD or number (%) of patients 
in the placebo or urokinase group. IV = intravenous; MI = myocardial 
infarction. 
between groups. Before admission, a similar percentage of 
patients were receiving beta-adrenergic blocking agents and 
aspirin. Before angioplasty, slightly more patients were 
receiving intravenous nitroglycerin in the urokinase than in 
the placebo group (42% vs. 30%). All patients were receiving 
either antithrombotic therapy or anticoagulant therapy, and 
a majority were receiving intravenous heparin before angio-
plasty (70% in the placebo group vs. 58% in the urokinase 
group). 
Baseline angiographic characteristics (Table 2). Of the 93 
patients who underwent angioplasty, 1 patient did not have a 
cine film available for review and was excluded from the 
angiographic analysis. In a majority of the remaining 92 
patients, the left anterior descending artery was the cUlprit 
vesseL However, there were no differences between the 
urokinase and placebo groups in the distribution of the 
culprit vesseL Six of 92 patients underwent angioplasty of a 
discrete lesion in a non degenerated saphenous vein graft. 
There were also no differences between groups in the 
incidence of calcified lesions, long lesions or filling defects 
before angioplasty. In addition, coronary morphology was 
similar between groups. Fifty-three percent of patent CUlprit 
lesions had a morphology that was eccentric and irregular 
(type II eccentric). There was also no significant difference 
between placebo or urokinase groups in the incidence of 
complex lesions (61% in the placebo group vs. 49% in the 
urokinase group, p = NS). Total coronary occlusions were 
found before angioplasty in 4% of patients. The mean TIMI 
flow was 2.6 for both groups. When coronary morphology 
was compared between trials A and B, the only significant 
difference was a higher percentage of complex lesions in trial 
B than in trial A (77% vs. 47%, respectively, p < 0.01). In 
Table 2. Baseline Angiographic Characteristics of the Patients in 
the Two Study Groups 
Placebo Urokinase 
Characteristic (n = 49) (n = 43) 
Culprit vessel 
LAD 24 (48) 24 (56) 
RCA 13 (26) 12 (28) 
LCx 10 (20) 3 (7) 
SVG 3 (6) 3 (9) 
Calcified lesions 3 (6) 2 (5) 
Long lesions (> 15 mm) 5 (10) 5 (12) 
Lesion morphology 
Concentric 4 (8) 9 (21) 
E. 15 (32) 12 (29) 
E2 28 (56) 18 (40) 
Total occlusion 1 (2) 4 (10) 
Complex lesions 30 (61) 21 (49) 
Filling defect before PTCA 2 (4) 4 (9) 
TIMI flow grade (mean) 2.6 2.6 
No differences between groups were significant. Unless otherwise indi-
cated, data are presented as mean value ± SD or number (%) of patients in the 
placebo or urokinase group. E. = eccentric regular; E2 = eccentric irregular; 
LAD = left anterior descending· coronary artery; LCx = left circumflex 
coronary artery; PTCA = percutaneous transluminal coronary angioplasty; 
RCA = right coronary artery; SVG = saphenous vein graft; TIMI = 
Thrombolysis in Myocardial Infarction. 
trial A, 50% of patients in the placebo group versus 38% of 
patients in the urokinase group had complex lesions. In trial 
B, the respective values were 79% and 67% (p = NS for 
both). The TIMI flow grades were similar in trial B and trial 
A. 
Results of angioplasty (Table 3, Fig. 2). There were no 
angiographic differences after infusion of urokinase or pla-
cebo in lesion morphology, TIMI flow grade or presence of 
filling defects. All 92 patients leaving the laboratory had 
successful procedures with residual lesions <50% by visual 
inspection. Of the 49 patients undergoing angioplasty in the 
placebo group, 14 patients (29%) developed a possible or 
definite filling defect at 15 ~in. There were seven definite 
Table 3. Angiographic Results 
Filling Defect 15 
Minutes After Acute 
Angioplasty Vessel 
(possible/definite) Closure 
Total group 
Placebo (n = 49) 7n (29) 4 (8) 
Urokinase (n = 43) 214 (14)* 4 (9) 
Trial A 
Placebo (n = 35) 3/5 (23) 2 (6) 
Urokinase (n = 31) 0/1 (3)t 0(0) 
Trial B 
Placebo (n = 14) 412 (43) 2 (14) 
Urokinase (n = 12) 213 (42) 4 (33) 
*p = 0.08, tp = 0.03, comparing the urokinase and placebo groups. Data 
are expressed as number (%) of patients in the specific placebo or urokinase 
group. 
AMBROSE ET AL. 1201 JACC Vol. 20. No.5 
November 1. 1992:1197-204 ADJUNCTIVE THROMBOLYTIC THERAPY FOR ANGIOPLASTY 
40 
~ 
z 
~ 30 
t:i Q. 
11. 
020 
f-
z 
W 
u 
a: 
~ 10 
rI:::~~~:: :~ 
.---p=Q.08--. 
Figure 2. Incidence of filling defects (FD) and acute vessel closure 
(AC) for the total study group. 
defects and seven possible defects. In the urokinase group 6 
(14%) of 42 developed a filling defect; two defects were 
possible and four were definite. This difference between 
groups approached significance (p < 0.08). Acute vessel 
closure was found in 8 (9%) of 92 patients and was equally 
distributed between groups. Three acute closures (one pa-
tient given urokinase and two given placebo) occurred 
during the angioplasty procedure, whereas the other five 
occurred at or after 15 min when the patients were still in the 
laboratory . 
Angioplasty results in trial A versus trial B (Table 3, Fig. 
3). Filling defects. When patients were classified into those 
in trial A (patients with unstable angina) versus trial B 
(patients with non-Q wave infarction and post-Q wave 
myocardial infarction with unstable angina), significant dif-
ferences were noted. In trial A there were significantly fewer 
filling defects at 15 min in the urokinase than in the placebo 
group (1 [3%] vs. 8 [23%], respectively, p = 0.03). In the 
placebo group there were three possible and five definite 
filling defects; there was only one definite filling defect in the 
urokinase group. On the other hand, there was a significantly 
higher incidence of filling defects in trial B than in trial A (11 
Figure 3. Incidence of filling defects (FD) and acute vessel closure 
(AC) for all patients in trial A and trial B. 
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Table 4. Procedural Results 
Angiographic Procedural Clinical Redilation 
Success Success Success (%) 
Total grDUp 
Placebo. (n = 49) 39 (80) 28 (57) 44 (90) 12 (25) 
Urokinase (n = 43) 32 (74) 34 (80) 40 (93) 6 (14) 
p value NS 0.03 NS NS 
Trial A 
Placebo. (n = 35) 25 (71) 24 (69) 31 (89) 6 (12) 
Urokinase (n = 31) 30 (97) 29 (94) 24 (83) 1 (3) 
p value <0.01 0.01 NS 0.1 
Trial B 
Placebo. (n = 14) 7 (50) 4 (29) 13 (87) 6 (40) 
Urokinase (n = 12) 5 (42) 5 (42) 10 (91) 5 (42) 
p value NS NS NS NS 
Data are expressed as number (%) Df patients in the specific placebo. or 
urDkinase group. Angiographic success = <50% stenDsis without a possible 
or definite filling defect or acute c1Dsure; Clinical success = successful 
corDnary angiDplasty withDUt myocardial infarction. cDronary artery bypass 
graft surgery Dr death; Procedural success = <50% stenDsis withDut a 
possible Dr definite filling defect acute vessel c1Dsure or the need fDr redilatiDn. 
[42.3%] vs. 9 [13.8%], respectively, p < 0.01). Furthermore, 
in trial B there were no differences between urokinase or 
placebo groups in the incidence of filling defects. Six patients 
in the placebo group developed filling defects (four possible 
and two definite defects) versus five patients in the urokinase 
group (two possible and three definite defects). All six culprit 
lesions in saphenous vein grafts were in trial A. No saphe-
nous vein lesion developed angiographic end points after 
angioplasty. 
Acute vessel closure. Of the eight acute closures, two 
(3%) occurred in trial A versus six (22%) in trial B (p < 0.01). 
In trial A there were no acute closures in patients treated 
with urokinase and two in patients treated with placebo. In 
trial B, there were two acute closures (14%) with placebo 
and 4 (33%) with urokinase. These differences were not 
significant. Two of four patients in each group (urokinase 
and placebo) with acute closure had thrombus at 15 min after 
angioplasty. 
Procedural results (Table 4). Angiographic, procedural 
and clinical success, as defined in the Methods section, is 
contained in Table 4. There were no differences between 
urokinase and placebo in the overall group except for a 
higher procedural success rate with urokinase (81% vs. 56%, 
p < 0.03). In trial A, both angiographic and procedural 
success were increased in patients treated with urokinase 
versus those given placebo (angiographic success, 97% vs. 
71%, p < 0.01; procedural success, 94% vs. 69%, p = 0.01). 
In trial B, there were no differences between treatment 
groups, in angiographic or procedural success. Clinical suc-
cess was similar for patients in trial A and trial B. Redilation 
was performed at 15 min in five of seven patients with 
definite thrombus treated with placebo and in three of four 
patients treated with urokinase. 
Coronary dissection. Dissections at 15 min were noted in 
13 placebo-treated patients (27%) versus 7 urokinase-treated 
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Table 5. In-Hospital Follow-Up Study 
Ischemia 
Myocardial infarction 
CABG 
Bleeding complications 
Baseline fibrinogen - post procedure 
fibrinogen (mg/dl) 
Placebo 
(n = 50) 
3 (6) 
2 (4) 
1 (2) 
11 (22) 
22.9 
Urokinase 
(n = 43) 
3 (7) 
1 (2) 
2 (5) 
4 (9) 
28.6 
No differences between groups were significant. Unless otherwise indi-
cated, data are expressed as number (%) of patients in the placebo or 
urokinase group. CABG = coronary artery bypass graft surgery; MI = 
myocardial infarction. 
patients (16%) (p = NS). In trial A, dissection was noted in 
10 placebo-treated patients (29%) versus 5 urokinase-treated 
patients (16%) (p = NS). In trial B, dissection was noted in 
3 placebo-treated patients (21%) versus 2 urokinase-treated 
patients (17%) (p = NS). 
Clinical in.hospital follow·up study (Table 5). Six patients 
(three from each group) developed ischemic chest pain with 
electrocardiographic changes after angioplasty. One of these 
later developed non-Q wave infarction, and three required 
coronary bypass surgery 2 to 24 h after the procedure. Two 
additional patients who were not from this group developed 
non-Q wave infarction (elevation of creatine kinase). Five of 
six patients with either infarction or coronary bypass surgery 
had a spiral coronary dissection or side branch occlusion, or 
both, as the presumed origin of their complication. 
Discussion 
Prior studies of thrombolytic therapy in association with 
coronaryangioplasty. The incidence of acute vessel closure 
during or immediately after angioplasty for unstable angina 
is greater than that of angioplasty for stable angina and has 
been reported to be between 4% and 12% (14-16). Of the two 
main mechanisms for acute vessel closure, thrombosis and 
dissection, there is substantial evidence suggesting that the 
incidence of thrombosis is increased. Both unstable angina 
and acute myocardial infarction share a common pathogen-
esis of plaque disruption and thrombus formation. Prior 
studies have indicated a higher incidence of acute vessel 
closure in both these syndromes in comparison with that in 
stable angina. The presence of angiographic thrombus for-
mation (filling defects) before angioplasty also increases the 
risk of acute closure after angioplasty in patients with 
unstable angina (17,18). 
Because of this potential association between thrombus 
formation and acute vessel closure during angioplasty in 
unstable angina, several studies have suggested a potential 
role for thrombolytic therapy in this situation. Nonrandom-
ized studies, some of which were retrospective, have found 
thrombolytic therapy beneficial in treating acute closure or 
as prophylactic management for certain high risk patients 
before angioplasty. Schieman et al. (4) prospectively studied 
75 patients with unstable angina or with postinfarction rest 
angina who underwent angioplasty and developed acute 
closure in the catheterization laboratory immediately after 
angioplasty, presumably secondary to thrombus formation. 
After infusion of 100,000 to 250,000 IU of intracoronary 
urokinase and in most cases redilation, there were no 
in-hospital deaths or procedure-related myocardial infarc-
tions, and only one patient required emergency bypass 
surgery. Other investigators have utilized intracoronary 
streptokinase or urokinase in varying dosages to treat acute 
vessel closure or as prophylaxis against acute closure in 
patients with thrombus formation detected before angio-
plasty (7,8). Anwar et al. (9) reported excellent angiographic 
success with 250,000 IU of intracoronary urokinase given 
immediately before angioplasty in 74 patients with either a 
duration of unstable angina < 1 week or with postinfarction 
rest angina. These groups were chosen on the basis of prior 
data indicating a high incidence of thrombotic closure after 
angioplasty (19). Because no study has randomized treat-
ment between drug and placebo, the actual role of throm-
bolytic therapy in these situations is difficult to assess. 
Furthermore, thrombolytic therapy administered during an-
gioplasty could theoretically be detrimental. Thrombin 
bound to fibrin is still active and may be released from within 
the thrombus by thrombolytic therapy, as well as by me-
chanical disruption by the balloon, resulting in further 
thrombosis (20). It has also been shown in acute myocardial 
infarction that angioplasty and thrombolytic therapy, when 
used concomitantly, may be associated with significant 
plaque hemorrhage leading to lumen compromise (21). 
Present study. The TAUSA trial is the first randomized 
double-blind, placebo-controlled trial to assess the possible 
efficacy of thrombolytic therapy as an adjunct to angioplasty 
in unstable angina. The results of the pilot study suggest a 
possible role for thrombolytic therapy as prophylaxis in 
patients undergoing angioplasty for unstable angina with rest 
pain but not after recent acute myocardial infarction whether 
non-Q or Q wave. Urokinase administration was safe and it 
decreased angiographic thrombus formation after angio-
pia sty in trial A. Whereas acute closure did not decrease 
after urokinase therapy, its incidence was probably reduced 
by the nearly routine use of redilation at 15 min after 
angioplasty in patients with definite filling defects. The fact 
that urokinase did not increase angiographic coronary dis-
section may suggest that increased plaque hemorrhage 
would be infrequent with a low dose of a thrombolytic agent. 
In-hospital myocardial infarction and the need for emer-
gency bypass surgery did not seem to be related in this study 
to the presence of in-laboratory acute closure or thrombus 
formation. Coronary dissection with or without side branch 
occlusion was demonstrated in five of six cases. Again, it is 
possible that if delayed angiographic views at 15 min were 
not routinely utilized, and redilation had not been performed 
successfully in all patients with acute closure and in most 
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with definite thrombi, different results would have been 
found for in-hospital complications. 
Mechanism of prevention of thrombus formation. How a 
short infusion of a thrombolytic agent given immediately 
before balloon dilation might prevent thrombus formation 
after angioplasty is unknown. A systemic fibrinolytic state 
was not demonstrated. Nevertheless, thrombus formation 
appeared to decrease in patients with unstable angina (trial 
A). Angioscopy in patients after angioplasty often demon-
strates thrombus formation with intimal dissection even 
when angiographically the site of dilation is widely patent 
and smooth-walled (22). Angiographic thrombus formation, 
as assessed in our study, probably represents only a large 
thrombus burden at the site of angioplasty-induced vessel 
injury. Platelet deposition followed by activation of both the 
intrinsic and the extrinsic pathways leads to thrombin gen-
eration with the formation of fibrin and further platelet 
aggregation at the site of injury. Stepwise activation of 
plasminogen by urokinase would serve to counteract these 
prothrombotic forces and lyse newly formed fibrin. 
We hypothesize that urokinase may have been more 
beneficial in unstable angina than in myocardial infarction 
because the latter is associated with a larger thrombus 
burden or with a greater degree of plaque disruption than is 
unstable angina. The higher incidence of complex lesions in 
trial B versus trial A is compatible with this hypothesis. Our 
data also suggest that only gross thrombus formation (angio-
graphically visible) can be prevented by urokinase adminis-
tration. Smaller amounts of thrombus formation could have 
been assessed only by angioscopy, which was not part of the 
protocol. Furthermore, because platelet deposition would 
not be expected to be decreased by this dose of urokinase, 
only the fibrin component of the thrombus might have been 
decreased by the thrombolytic agent. 
Study limitations. There are several limitations to this 
pilot study: 
1. The sample size was small, therefore increasing the 
chance of a type II error. However, this was only a pilot 
study and a larger trial involving several hundred patients 
has just been completed. This larger trial will allow for a 
more detailed analysis of clinical and angiographic factors 
influencing angioplasty outcome for ischemic rest angina, for 
example, duration and acuteness of the syndrome, timing of 
angioplasty, influence of preangioplasty clinical and angio-
graphic variables on the outcome ofangioplasty, and others. 
In addition, large numbers will be required to assess whether 
or not clinical end points, that is, recurrent ischemia or 
infarction, will be decreased by urokinase after angioplasty. 
2. The optimal dose and duration of infusion of urokinase 
are also unknown. The selection of a low dose of urokinase, 
as chosen in the pilot study, was intentional so as to minimize 
complications. It is hoped that the use of higher doses at 
different rates of infusion in the ongoing trial will help to 
establish a dose-response curve for urokinase in angioplasty. 
3. Another potential limitation is related to the use of a 
fixed dose of heparin without use of the activated coagula-
tion time to monitor anticoagulant therapy. Recent data 
suggest that 10,000 U of heparin may be insufficient to 
increase the activated coagulation time to >300 s in some 
patients with unstable angina (23,24). Furthermore, lower 
activated coagulation times have been associated with an 
increased incidence of thrombus formation or acute closure 
at the time of angioplasty. 
4. The choice of 15 min as the angiographic end point was 
somewhat arbitrary. However, delayed views were utilized 
by other investigators assessing the importance of aspirin in 
preventing acute closure in angioplasty (25). Because all 
participating centers represented busy catheterization labo-
ratories, selection of an interval > 15 min was considered 
impractical. Whether the same results from this study would 
have been seen if 30-min angiograms or repeat injections on 
the day after angioplasty had been peIformed remains to be 
seen. . 
5. Finally, there is no certain method for defining throm-
bus angiographically. Although we presumed that the pres-
ence of definite filling defects represented thrombus, the 
angiographic significance of possible thrombus is unknown. 
Because many angioplasty results appear hazy or translu-
cent but without filling defects, we believed that ignoring 
these findings might decrease the sensitivity of our findings. 
In addition, as mentioned earlier, angiographic analysis of 
thrombus probably represents a large thrombus burden. 
Lesser amounts of thrombus require angioscopic evaluation 
for detection. 
Conclusions. These data suggest that intracoronary 
urokinase may have a potential role in reducing presumed 
thrombus formation after angioplasty when this drug is given 
immediately before angioplasty for patients with unstable 
angina without recent infarction. However, even though 
angiographic and procedural success as defined in this study 
was significantly higher in patients with unstable angina 
randomized to urokinase, the significance of these findings 
remains to be determined. Intracoronary urokinase in the 
dose utilized was ineffective after angioplasty after myocar-
dial infarction. In-hospital myocardial infarction and emer-
gency coronary bypass were not predicted by the presence 
of intracoronary thrombus, although redilation may' have 
decreased the incidence of these complications. The findings 
of this pilot study need to be reevaluated in a larger study 
utilizing higher doses of urokinase at different rates of 
infusion. Heparin effect will also need to be measured to 
ensure adequate anticoagulation during the procedure. The 
TAUSA trial has randomized several hundred patients in an 
attempt to definitively answer these questions. 
Appendix 
Thrombolysis and Angioplasty in Unstable 
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BS; Denise Ratner, RN. 
Collaborating Centers. Westchester County Medical Center, Valhalla, 
NY: Melvin B. Weiss, MD; Craig E. Hjemdahl·Monsen, MD. Philadelphia 
Heart Institute, Philadelphia, PA: William J. Untereker, MD;James Marshall, 
DO. Long Island Jewish Medical Center, New Hyde Park, NY: Andrew M. 
Grunwald, MD; Jerome Koss, MD. Lenox Hill Hospital, New York, NY: 
Jeffrey Moses, MD; James Wilentz, MD; Edward Kreps, MD. 
Angiograpbic Core Laboratory. Mount Sinai Medical Center: John A. 
Ambrose, MD; Sabino R. Torre, MD; Susan LaForgia, BS. 
Statistical Analysis. Nick Teoh, PhD. Abbott Laboratories. Data Monitor-
ing Board: Paul Bunnell, CRA; John Sobolski, MD, PhD; Walter M. Barker, 
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